Developing Story
Valemetostat (EZH1/2 Inhibitor) – Immunotherapy Enhancement in Lung Cancer (2026)
A June 2026 preprint reports that valemetostat, an EZH1/2 inhibitor, enhances anti-PD1 immunotherapy responses in squamous cell lung cancer by upregulating MHC Class II expression and reprogramming neutrophils. The finding suggests a novel epigenetic mechanism for overcoming immunotherapy resistance in a difficult-to-treat cancer. Clinical translation and IP implications are significant for life sciences investors and pharma attorneys.
Importance: 63%Confidence: 72%Mentions: 1Updated: June 7, 2026
## Valemetostat (EZH1/2 Inhibitor) – Immunotherapy Enhancement in Lung Cancer (2026)
### Overview
Research published in June 2026 demonstrates that valemetostat, an EZH1/2 inhibitor, reportedly improves anti-PD1 immunotherapy responses in squamous cell lung cancer models through MHC Class II de-repression and neutrophil reprogramming (bioRxiv, June 1, 2026).
### Key Findings
- **Mechanism:** Valemetostat upregulates tumor cell-specific MHC Class II expression, enhancing immune recognition (bioRxiv, June 1, 2026)
- **Immune effects:** Produces a shift toward activated CD8+ T cells and reprograms neutrophil populations (bioRxiv, June 1, 2026)
- **Model context:** Squamous cell carcinoma of the lung, described as difficult to treat with high US prevalence, particularly in Kentucky (bioRxiv, June 1, 2026)
- **Ex vivo models:** Study also develops ex vivo platforms to test immunotherapy drug combinations (bioRxiv, June 1, 2026)
- **Status:** Preprint; not yet peer-reviewed
### Context
Squamous cell lung carcinoma remains one of the most treatment-resistant thoracic cancers, with limited targeted therapy options compared to adenocarcinoma. EZH1/2 inhibitors represent an epigenetic approach to reversing immune evasion. Valemetostat is already approved in Japan for certain T-cell lymphomas, making the repurposing pathway potentially accelerated.
### Strategic Relevance
For life sciences investors and pharma attorneys, valemetostat's combination potential with checkpoint inhibitors (anti-PD1) in squamous cell lung cancer represents a significant commercial opportunity if clinical translation succeeds. The MHC Class II upregulation mechanism is a novel and potentially broadly applicable approach to overcoming immunotherapy resistance. IP positioning around this combination approach warrants monitoring.